全文获取类型
收费全文 | 878篇 |
免费 | 29篇 |
国内免费 | 65篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 54篇 |
妇产科学 | 10篇 |
基础医学 | 62篇 |
口腔科学 | 36篇 |
临床医学 | 134篇 |
内科学 | 210篇 |
皮肤病学 | 25篇 |
神经病学 | 12篇 |
特种医学 | 244篇 |
外科学 | 43篇 |
综合类 | 29篇 |
预防医学 | 26篇 |
眼科学 | 14篇 |
药学 | 36篇 |
肿瘤学 | 35篇 |
出版年
2021年 | 6篇 |
2020年 | 3篇 |
2019年 | 3篇 |
2018年 | 3篇 |
2017年 | 5篇 |
2016年 | 5篇 |
2015年 | 14篇 |
2014年 | 12篇 |
2013年 | 22篇 |
2012年 | 11篇 |
2011年 | 10篇 |
2010年 | 28篇 |
2009年 | 38篇 |
2008年 | 13篇 |
2007年 | 57篇 |
2006年 | 21篇 |
2005年 | 16篇 |
2004年 | 9篇 |
2003年 | 6篇 |
2002年 | 11篇 |
2001年 | 13篇 |
2000年 | 10篇 |
1999年 | 13篇 |
1998年 | 60篇 |
1997年 | 69篇 |
1996年 | 70篇 |
1995年 | 59篇 |
1994年 | 42篇 |
1993年 | 49篇 |
1992年 | 8篇 |
1991年 | 14篇 |
1990年 | 13篇 |
1989年 | 39篇 |
1988年 | 22篇 |
1987年 | 36篇 |
1986年 | 12篇 |
1985年 | 24篇 |
1984年 | 15篇 |
1983年 | 23篇 |
1982年 | 19篇 |
1981年 | 17篇 |
1980年 | 20篇 |
1978年 | 5篇 |
1977年 | 9篇 |
1976年 | 4篇 |
1975年 | 6篇 |
1966年 | 2篇 |
1948年 | 1篇 |
1947年 | 1篇 |
1927年 | 2篇 |
排序方式: 共有972条查询结果,搜索用时 46 毫秒
971.
Wang YC Morrison G Gillihan R Guo J Ward RM Fu X Botero MF Healy NA Hilsenbeck SG Phillips GL Chamness GC Rimawi MF Osborne CK Schiff R 《Breast cancer research : BCR》2011,13(6):R121-19
Introduction
The human epidermal growth factor receptor 2 (HER2)-targeted therapies trastuzumab (T) and lapatinib (L) show high efficacy in patients with HER2-positive breast cancer, but resistance is prevalent. Here we investigate resistance mechanisms to each drug alone, or to their combination using a large panel of HER2-positive cell lines made resistant to these drugs.Methods
Response to L + T treatment was characterized in a panel of 13 HER2-positive cell lines to identify lines that were de novo resistant. Acquired resistant lines were then established by long-term exposure to increasing drug concentrations. Levels and activity of HER2 and estrogen receptor (ER) pathways were determined by qRT-PCR, immunohistochemistry, and immunoblotting assays. Cell growth, proliferation, and apoptosis in parental cells and resistant derivatives were assessed in response to inhibition of HER or ER pathways, either pharmacologically (L, T, L + T, or fulvestrant) or by using siRNAs. Efficacy of combined endocrine and anti-HER2 therapies was studied in vivo using UACC-812 xenografts.Results
ER or its downstream products increased in four out of the five ER+/HER2+ lines, and was evident in one of the two intrinsically resistant lines. In UACC-812 and BT474 parental and resistant derivatives, HER2 inhibition by T reactivated HER network activity to promote resistance. T-resistant lines remained sensitive to HER2 inhibition by either L or HER2 siRNA. With more complete HER2 blockade, resistance to L-containing regimens required the activation of a redundant survival pathway, ER, which was up-regulated and promoted survival via various Bcl2 family members. These L- and L + T-resistant lines were responsive to fulvestrant and to ER siRNA. However, after prolonged treatment with L, but not L + T, BT474 cells switched from depending on ER as a survival pathway, to relying again on the HER network (increased HER2, HER3, and receptor ligands) to overcome L's effects. The combination of endocrine and L + T HER2-targeted therapies achieved complete tumor regression and prevented development of resistance in UACC-812 xenografts.Conclusions
Combined L + T treatment provides a more complete and stable inhibition of the HER network. With sustained HER2 inhibition, ER functions as a key escape/survival pathway in ER-positive/HER2-positive cells. Complete blockade of the HER network, together with ER inhibition, may provide optimal therapy in selected patients. 相似文献972.
ME Bradley ME Bond J Manini Z Brown SJ Charlton 《British journal of pharmacology》2009,158(1):328-338